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SHORT COMMUNICATION
Decreased production of soluble interleukin 2 receptor by
phytohaemagglutinin-stimulated peripheral blood mononuclear cells in
patients with breast cancer after adjuvant therapy
C.C. Zielinski, Ch. Muller', E Tichatschek & P. Aiginger
II Department of Medicine and 'II Department ofGastroenterology and Hepatology, University Hospital, and the Ludwig
Bolt-mann Institutfiir prdnatale und experimentelle Genomanalytik, A-1090 Vienna, Austria.
Adjuvant chemotherapy has become an universally accepted
approach to certain patients with breast cancer in that it has
resulted in a prolongation of the disease-free interval (DFI)
in defined subgroups (Consensus Development Conference
Committee, 1986; Editorial, 1986). However, long-term side
effects of adjuvant cytostatic measures have not been clearly
defined (Consensus Development Conference Committee,
1986). Recently, we have reported a prolonged effect of
adjuvant chemotherapy with cyclophosphamide, methotrex-
ate and fluoruracil (CMF; Bonadonna et al., 1977) in era-
dicating primary antibody production (Zielinski et al., 1986)
and, like other authors (Blomgren et al., 1980; Levy et al.,
1987), we have reported changes in natural killer cell activity
after adjuvant treatment (Tichatschek et al., 1988). We have
now investigated the impact of adjuvant radio- and/or
chemotherapy in breast cancer upon T cell activation
(Rubin et al., 1985), and have studied soluble interleukin 2
receptor (sIL-2R) concentrations in serum and in super-
natants of phytohaemagglutinin (PHA) stimulated
peripheral blood mononuclear cells (PBMC) derived from
patients with breast cancer after various adjuvant treatment
modalities.
A total of 54 female patients (mean age: 59.2±2.3 years)
with breast cancer was included in the study. The patients
consisted of two groups as follows.
Group 1 contained 31 patients with stage II breast cancer
in the DFI without clinical or serological signs of metastases
up to 6 months after being included in the present study. Six
to 36 months before being entered into the investigation,
patients had terminated one the following adjuvant treatment
schedules: (a) megavoltage radiotherapy with a total dose of
5,000 rad to the thoracic wall and the draining lymph nodes
(n = 6); (b) chemotherapy with six courses of cyclophos-
phamide, methotrexate and fluoruracil (CMF (Bonadonna et
al., 1977), n = 8); (c) both treatment modalities (n = 10); (d)
surgical removal of the tumour and axillar lymphnodes with-
out any subsequent adjuvant treatment (n = 7).
Group 2 contained 23 patients with distant metastases who
were undergoing combined cytostatic chemotherapy includ-
ing adriamycin or mitoxantrone. Each course of cytostatic
treatment had been administered 4 weeks before the inclusion
of the patients in the present study.
As controls, 38 healthy age-adjusted female control per-
sons were investigated in parallel.
PBMC were separated by a buoyant density gradient on
(Boyum, 1968) on Ficoll-Hypaque (Pharmacia, Uppsala,
Sweden) from freshly drawn heparinised (preservative free
heparin, Immuno AG, Vienna, Austria) peripheral venous
blood, washed three times in 0.9% saline and resuspended to
1 x 106 PBMC ml-' in RPMI 1640 media (Gibco, Paisley,
UK) supplemented with 10% fetal calf serum (Flow Labs,
UK), 100 IU penicillin ml-', 100 tLg streptomycin ml-' and
2mM L-glutamine (Gibco).
PBMC 100l1p adjusted to I x 106ml-' was pipetted in
triplicate into wells of a 96-well microtitre plate (Costar,
Cambridge, MA, USA) together with 100 "Il culture medium
RPMI 1640 supplemented with 10% fetal calf serum and
with 20 tlI PHA (final dilution 1:100). Control wells without
mitogen were included in each experiment. The cultures were
incubated at 37°C in a humidified atmosphere containing 5%
CO2 for 7 days. This period has been shown to be optimal
for the generation of IL-2R in the supernatant of PHA-
stimulated PBMC in previous studies (Rubin et al., 1985).
Sixteen hours before the end of the culture period, 100 lp of
the culture supernatant was carefully removed and stored at
-20°C for sIL-2R determination. Subsequently, 100til of
supplemented medium RPMI 1640 and 20 of 3H-thymidine
(185 GBq ml-'; Amersham, UK) were added and incubated
for the remaining time. Cells were harvested with an auto-
matic harvester, and the incorporation of the radioactive
compound into proliferating cells was determined by liquid
scintillation in a beta-counter.
sIL-2R concentrations were assessed in duplicate samples
of either serum or supernatant of PHA-stimulated (final con-
centration: 1:100) PBMC applying a sandwich enzyme immu-
noassay (Cellfree, T Cell Sciences Inc., Cambridge, MA,
USA) according to the method of Rubin et al. (1985). The
measurement of sIL-2R levels was performed in two batches
(i.e. sera and supernatants) with all samples derived from
patients and controls tested simultaneously. In brief, the
sIL-2R present in test samples or in standards binds to
polystyrene microtitre wells previously incubated with 100 il
anti-IL-2R monoclonal antibody (1 jtg ml-'). A horseradish
peroxidase-conjugated anti-IL-2R monoclonal antibody
directed against a second epitope on the sIL-2R molecule
binds to the sIL-2R captured by the first antibody. After a
washing step to remove unbound enzyme-conjugated anti-
sIL-2R antibody, a substrate solution was added to the wells,
the reaction was stopped after 30min and the absorbence
was determined at 490 nm. A standard curve was prepared
from four sIL-2R standards. The sIL-2R standard was the
cell-free supernatant obtained from PHA-stimulated T cells
assigned a value of 1,000 U ml-'.
All data are expressed as mean ± standard deviation.
Comparisons between groups were carried out using Stu-
dent's t test. Correlation was calculated by Pearson's correla-
tion coefficient.
sIL-2R levels assessed in sera derived from patients with
non-metastatic (319.7 ± 100.3 U ml-') or metastatic
(440.9 ± 183.4 U ml- ') breast cancer or from healthy control
individuals (404.2 ± 245 U ml-') did not differ significantly
from each other (P>0. 1, respectively).
When sIL-2R levels were assessed in supernatants from
PHA-stimulated PBMC derived from either patients or heal-
thy controls, clear-cut differences could be found between the
various groups. As shown in Table I, healthy controls were
found to produce sIL-2R in an amount that was significantly
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higher than levels fround in both patient groups, i.e. with
non-metastatic as well as with metastatic disease under
immediate cytostatic treatment (see above). Moreover, a
significant difference was found in PHA-stimulated sIL-2R
production between patients with or without metastases
(P<0.0005 ).
Table I also shows that adjuvant radio-and chemotherapy
both resulted in a significant and long-lasting effect upon
PHA-induced sIL-2R levels. Thus, patients after adjuvant
radio-or chemotherapy had significantly lower sIL-2R con-
centrations in their supernatants following PHA stimulation
of PBMC than either patients in the DFI who had not
received any adjuvant treatment or healthy control individ-
uals (P<0.0005, respectively), whereas the results of the lat-
ter two groups were almost identical (P>0.1). Patients who
had received combined adjuvant treatment (i.e. radio- and
chemotherapy) did not differ in their PHA-induced sIL-2R
production from patients treated by either approach
(P>O.l).
In order to understand further the findings of PHA-
stimulated sIL-2R production, we have investigated in simul-
taneous experiments the ability of PBMC derived from the
various groups of patients or from healthy control individ-
uals to proliferate in response to stimulation with identical
concentrations of PHA used for the induction of sIL-2R
production. As shown in Table I, control individuals had
significantly increased values over both patients in the DFI
after adjuvant therapy (P>0.0025) and patients with metas-
tatic disease (P<0.0005). Table I further shows that patients
with non-metastatic disease after adjuvant radio and/or
chemotherapy had experienced a long-lasting and significant
decrease in PHA-stimulated proliferation, as compared to
healthy controls (P<0.01 and P<0.025, respectively). In
contrast, PHA-induced proliferation of PBMC dervived from
patients with breast cancer who had not received adjuvant
treatment did not differ significantly from the one obtained in
control patients (P>0.1).
A strong correlation (r = 0.72) was found between PHA-
induced sIL-2R concentrations and results obtained in simul-
taneous experiments assessing mitogenic stimulation of
PBMC by PHA. This result further corroborated the
assumption of a reduced T cell responsiveness in patients
after adjuvant treatment.
In the present investigation, we have studied levels of
sIL-2R in sera and in supernatants of PHA-stimulated
PBMC derived from patients with various stages of breast
cancer. Although the investigated groups of patients, i.e. with
non-metastatic and metastatic breast cancer as well as
healthy controls, did not differ in their sIL-2R serum content,
it was found that patients with metastatic breast cancer
under cytostatic treatment as well as patients in the DFI as
long as 6-36 months after the termination of adjuvant treat-
ment had significantly lower sIL-2R levels in the super-
natants of cultures of PHA-stimulated PBMC than healthy
controls. No difference concerning sIL-2R levels was found
between patients who had received adjuvant radiotherapy
and those after adjuvant CMF treatment. Surprisingly,
patients with breast cancer in the DFI who had not under-
gone any adjuvant treatment had comparable sIL-2R concen-
trations in the supernatants of their PHA-stimulated PBMC
as healthy controls. It was thus tempting to assume that
adjuvant treatment consisting of radio- or chemotherapy led
to a long-lasting decrease of sIL-2R production upon PHA
stimulation of PBMC in vitro. These findings fit well into the
concept of an association of chemotherapy with several
features of immune dysregulation (Berenbaum, 1974; Harris
et al., 1976; Heppner & Calabresi, 1976; Schwartz et al.,
1959).
Interleukin 2 leads to the proliferation of T cells via its
receptor which is expressed on activated, but not resting T
cells (Greene et al., 1986; Wang & Smith, 1987) and which
can be induced by mitogenic stimulation (Robb et al., 1984).
The membrane-bound interleukin 2 receptor can be released
and transformed into a soluble form (Levy et al., 1987)
which - although not completely identical (Rubin et al.,
1986; Yannic et al., 1987) - retains its ability to bind
interleukin 2 (Rubin et al., 1986). Thus, our findings on the
sIL-2R in supernatants of PHA-stimulated PBMC gained an
additional aspect by the results obtained in simultaneous
experiments in which also the proliferation of PBMC follow-
ing mitogenic stimulation with PHA was studied. The iden-
tical patients after 6-36 months after termination of
adjuvant radio- or chemotherapy were found to have a
significantly decreased PHA-induced proliferation of their
PBMC as compared to healthy controls, and the results of
mitogen-driven proliferation were also found to be com-
parable to data obtained in patients with metastatic disease
under immediate cytostatic treatment. In order to exclude the
possibility that the presented results might be due to a
decrease of circulating T cells or IL-2R cells in patients with
breast cancer, experiments assessing T cell phenotypes are
being currently performed in our laboratory. However, the
strong correlation of PHA-induced sIL-2R concentrations
with the PHA-driven proliferation of PBMC would argue for
the assumption of a general decrease of T cell responsiveness
in the investigated population of patients. It is surprising,
nevertheless, that the effect of adjuvant therapeutic measures
could be observed after a very prolonged time after the
termination of treatment, thus further adding evidence of the
impact of adjuvant therapy upon various aspects of the
immune system.
The authors are grateful to Ms W. Kalinowski and Ms D. Peter-
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Table I Production ofsIL-2R by PHA-stimulated peripheral blood mononuclear cells and PHA-induced
proliferation of PBMC dervived from patients with breast cancer and healthy control individuals
Population sIL-2R (U/mi) pa d.p.m. pa
Healthy controls (n = 38) 953.7±408.3 25.218± 12.512
Patients w/o metastases (n = 31) 625.3± 362.3 <0.0005 16.416±7.785 <0.025
After adjuvant radiotherapy (n = 16b) 474.4±221.8 <0.0005 16.920±6.901 <0.01
After adjuvant chemotherapy (n = 8) 472.5±276.7 <0.0005 12.677±5.650 <0.025
No adjuvant treatment (n = 7) 947.2± 313.0 >0.1 20.839± 6.637 >0.1
Patients with metastases (n = 23) 288.9± 180.4 <0.0005 11.756± 12.637 <0.0005
aAgainst data obtained in healthy controls. bIncluding 10 patients after adjuvant radio-and
chemotherapy.714 C.C. ZIELINSKI et al.
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